India Markets close in 1 hr 54 mins
  • BSE SENSEX

    40,158.97
    -526.53 (-1.29%)
     
  • Nifty 50

    11,770.00
    -160.35 (-1.34%)
     
  • USD/INR

    73.8950
    +0.0250 (+0.0338%)
     
  • Dow

    28,335.57
    -28.13 (-0.10%)
     
  • Nasdaq

    11,548.28
    +42.28 (+0.37%)
     
  • BTC-INR

    963,941.56
    -1,614.31 (-0.17%)
     
  • CMC Crypto 200

    262.04
    +0.58 (+0.22%)
     
  • Hang Seng

    24,918.78
    +132.68 (+0.54%)
     
  • Nikkei

    23,494.34
    -22.25 (-0.09%)
     
  • EUR/INR

    87.4252
    -0.2204 (-0.25%)
     
  • GBP/INR

    96.0857
    -0.2382 (-0.25%)
     
  • AED/INR

    20.0670
    0.0000 (0.00%)
     
  • INR/JPY

    1.4167
    +0.0023 (+0.16%)
     
  • SGD/INR

    54.3160
    -0.0900 (-0.17%)
     

Dr. Reddy's at a lifetime high;Albuterol Boost comes in for Cipla & Lupin |Top headlines | 18th Sept

Here are the top headlines:
1. OPENING BELL: Sensex rises 170 points, Nifty above 11,550; Lupin jumps 5%, Cipla 3% | September 18
-Domestic markets followed Asian peers to open higher in Friday's session, led by gains in RIL, ICICI Bank, TCS, and HDFC Bank. Pharma stocks were buzzing in the morning session, rising up to 10%.
Vodafone Idea, Essel Propack, YES Bank among the most active stocks on NSE. The numbers today in the pharma industries are all in green, Dr. Reddy's Lab stands at 4972. Lupin is at 1075. Cipla stands at 781. Nacto Pharma is at 803.
The entire pharma basket is what is holding up the trade. In pharma industries Q1 numbers were good and the kind of approvals pharma industries received, it is a sector that is roaring currently. There is earnings support, perception change with under ownership.

2. Albuterol Boost comes in for Cipla & Lupin; Perrigo’s exit to benefit both?
-The market is clearly all about the pharma today. Apart from DRL and the big boost that it has received today, Cipla and Lupin continue to be amongst the top stocks.
Albuterol Boost comes in for Cipla, and it came in the month of April and they have got 10%+ market share and Lupin got the approval very recently. Lupin seems to have got the batches as what has been told by the company to ET Now. Perrigo which is one of the important players has gone ahead and withdrawn the drug.
According to the analysts, Cipla &Lupin are already in the market with Albuterol and that this is an opportunity to gain till Perrigo comes back.

3. Dr Reddy settles Patent Litigation Suit; big boost for pharma sector
-Pharma stocks clearly own the market as of now and the recent rising trend has brought all the attention towards the pharma stocks, but most importantly on DRL. DRL has settled the patent litigation suit of US Revlimid Capsules and has been the outperforming stock since quite some time now, and is likely to maintain its position as an outperforming stock in the near future.
According to JP Morgan, gRevlimid settlement is positive and it could improve US visibility but could be competitive as well. Furthermore, Dr Reddy has seen an improved outlook in the US business. The launch of gVascepa in the near-term will be a key catalyst, states JP Morgan’s report.